Pfizer (NYSE:PFE) Shares Down 3.9% - Time to Sell?

Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price fell 3.9% on Thursday . The company traded as low as $21.57 and last traded at $21.61. 16,763,261 shares traded hands during trading, a decline of 58% from the average session volume of 39,955,145 shares. The stock had previously closed at $22.49.

Wall Street Analysts Forecast Growth

Several analysts have commented on PFE shares. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group cut their price objective on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 8th. Finally, Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $31.07.

Pfizer Trading Up 0.9 %

The stock's fifty day simple moving average is $25.25 and its 200-day simple moving average is $26.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market cap of $125.34 billion, a PE ratio of 15.67, a PEG ratio of 0.64 and a beta of 0.67.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period last year, the firm posted $0.10 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Activity

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.06% of the company's stock.

Hedge Funds Weigh In On Pfizer

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the 4th quarter worth about $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer in the fourth quarter worth approximately $27,000. Gould Capital LLC increased its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the 4th quarter valued at $28,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.